Welcome to our dedicated page for Addex Therapeutics news (Ticker: ADXN), a resource for investors and traders seeking the latest updates and insights on Addex Therapeutics stock.
Addex Therapeutics Ltd. reports developments as a Swiss clinical-stage biopharmaceutical company developing orally available small-molecule allosteric modulators. News commonly centers on its neurological-disorder portfolio, including GABAB positive allosteric modulators, metabotropic glutamate receptor programs such as mGlu5, mGlu7 and mGlu2, and muscarinic M4 PAM work associated with its Neurosterix spin-out.
Company updates also cover research collaborations, preclinical data, clinical-study activity, intellectual-property and licensing arrangements, strategic investments, financial results, and ADR-related public-company disclosures for ADXN.
Enamine Ltd. has extended its collaboration with Addex Therapeutics Ltd (ADXN), enhancing its drug discovery services in CNS small molecules. Enamine will utilize its extensive resources and expertise in medicinal chemistry and pharmacology to support Addex's research programs under a Full Time Equivalent (FTE) model. Enamine's innovation and large collection of over 225,000 building blocks are expected to positively impact Addex's lead finding activities. This partnership builds upon years of successful collaboration and will continue to foster advancements in drug discovery.